Clinical trials: Solid Tumors, completed
Malignant Solid Tumour
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
There is a great need for new therapies for carcinomas that have progressed on or not responded to current therapy. There are no approved Met targeted agents in standard clinical use.
- Trial name
- NCT01721148
- Testing
- ASLAN002( BMS 777607)
- Volunteers
- 39 people
- Sponsor
- ASLAN Pharmaceuticals
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
RATIONALE: A computer-based survey and communication aid may help physicians and patients to communicate better and help make treatment decisions easier.
- Trial name
- NCT00244868
- Testing
- counseling intervention, educational intervention
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer, Renal Pelvis Cancer
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to test the safety of gemcitabine and cisplatin plus Everolimus (also called RAD001) at different dose levels.
- Conditions
- Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- NCT01182168
- Testing
- gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Pain
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
RATIONALE: Percutaneous cryoablation may help relieve pain caused by bone metastases. PURPOSE: This clinical trial is studying the side effects and how well percutaneous cryoablation works in treating patients with painful bone…
- Conditions
- Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00608855
- Testing
- questionnaire administration, cryosurgery, pain therapy
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy
This clinical trial evaluates whether acupressure is helpful to reduce anxiety related to chemotherapy. Anxiety is experienced by many patients with cancer.
- Trial name
- NCT06322615
- Testing
- Acupressure Therapy, Educational Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Solid Tumor in Advanced Stage
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Evaluation of pharmacokinetic profile of SPARC1028
- Trial name
- NCT01305512
- Testing
- SPARC1028
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Neoplasm Metastases, Hepatic Insufficiency
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
- Trial name
- NCT01273493
- Testing
- Trabectedin, Dexamethasone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Anemia, Fatigue
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
RATIONALE: Exercise may decrease anemia-related fatigue, improve strength, and build up lost muscle tissue. Epoetin alfa may help improve cancer-related anemia, energy levels, and quality of life.
- Conditions
- Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004914
- Testing
- epoetin alfa, physical therapy
- Where
- United States
- Sponsor
- Northwestern University
Advanced Solid Tumors, Lymphomas
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
The purpose of this study was to determine the metabolism and elimination of 14C-lenvatinib in participants with advanced solid tumors or lymphomas, who were unsuitable for, or had failed, existing therapies.
- Trial name
- NCT02578316
- Testing
- Lenvatinib
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006464
- Testing
- 7-hydroxystaurosporine, cisplatin
- Where
- 4 sites in United States
- Sponsor
- City of Hope Medical Center
Neutropenia
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without…
- Trial name
- NCT02190721
- Testing
- tbo-filgrastim
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Advanced Solid Tumors
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
- Trial name
- NCT02900157
- Testing
- MEDI9090, Durvalumab
- Where
- 8 sites in United States, Japan
- Volunteers
- 42 people
- Sponsor
- MedImmune LLC
Unspecified Adult Solid Tumor, Protocol Specific
Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy
RATIONALE: Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life of cancer survivors.
- Trial name
- NCT01019187
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Fatigue Assessment and Management
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Solid Tumors
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: the safety profile, the highest dose of IPI-504 that can be given with docetaxel without…
- Trial name
- NCT00606814
- Testing
- IPI-504, docetaxel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Solid Tumor, Lymphoma
Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma
This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part…
- Trial name
- NCT04977167
- Testing
- HG146, PD-(L)1 antibody
- Where
- China
- Volunteers
- 24 people
- Sponsor
- HitGen Inc.
Solid Tumors, Advanced Cancer
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
The primary purpose of this study is to determine the highest dose of ON 01910.Na that can be safely given as an intravenous infusion over 24 hours once a week in a 3-week cycle to patients with advanced solid tumors.
- Conditions
- Solid Tumors, Advanced Cancer, Cancer, Neoplasms
- Trial name
- NCT01538563
- Testing
- rigosertib sodium
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Traws Pharma, Inc.
Solid Tumor
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and…
- Trial name
- NCT02048709
- Testing
- GDC-0919
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced solid…
- Trial name
- NCT00003709
- Testing
- carbendazim
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
This is a first-in-man trial, in which BYL719 will be administered to adult patients with advanced solid tumors, whose tumors have an alteration of the PIK3CA gene and whose disease has progressed despite standard therapy or for…
- Trial name
- NCT01219699
- Testing
- BYL719, Fulvestrant
- Where
- 11 sites in United States, Germany and 3 more
- Volunteers
- 221 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.